Sign in
Enrolling by invitationNo phase

Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)

Key facts

Who runs it
Yanqing Li
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
288 people, planned
Started
1 Mar 2025
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Pinaverium bromide
  • Placebo for control group
Record updated
20 April 2025

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Gender is not limited, age range is 18-85 years old (inclusive)
  • Perform P-ESWL treatment for painful chronic pancreatitis with positive pancreatic duct stones ≥ 5mm, mainly located in the head or body of the pancreas

Who cannot take part

  • Acute pancreatitis within 3 days prior to ESWL
  • Chronic pinaverium bromide use with <3-day washout period
  • Severe cardiac/pulmonary dysfunction precluding anesthesia tolerance
  • Advanced liver disease (e.g., liver failure, cirrhosis, ascites, abscess)
  • Suspected or confirmed pancreatic malignancy
  • Known allergy to pinaverium bromide
  • Requiring repeat ESWL during the study period
  • Anticoagulant use within 3 days or coagulopathy
  • Arteriosclerosis or aortic aneurysm along shockwave transmission path
  • Pregnancy or lactation
  • Declined participation

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate whether perioperative pinaverium bromide (a calcium antagonist) reduces post-ESWL complications (pancreatitis, abdominal pain, infection) in chronic pancreatitis patients with pancreatic duct stones ≥5mm. A single-center, randomized, double-blind, placebo-controlled design will be used, with 288 participants allocated to either pinaverium bromide (100mg tid) or placebo before and after p-ESWL.

The 2 groups in the trial

  • Pinaverium BromideTreatment being tested

    Preoperative, intraoperative, and postoperative oral administration of 100mg tid of povidone bromide in p-ESWL

  • PlaceboPlacebo, for comparison

    Preoperative, intraoperative, and postoperative oral administration of 100mg tid of placebo in p-ESWL

    Treatment: Placebo for control group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP): a Single-center, Double-blind, Randomized, Placebo-controlled Trial.
Criteria questions
Built from NCT06936800, who can take part
Record updated
20 April 2025